methylated sites at reelin and GAD67 promoters, [(Fig. 1) and Dong et al., 2007], thus
preventing the recruitment of a corepressor protein complex. This complex includes methyl-
CpG-binding domain proteins (MeCP2, MDB2, MBD4), DNMTs, and other corepressor
proteins (Dong et al., 2007). We have shown that if HDAC inhibitors such as VPA and the
benzamide derivative MS-275 are given to mice after methionine withdrawal, they
dramatically accelerate reelin and GAD67 promoter demethylation during the subsequent
24–48 hours (Fig. 1 and Dong et al., 2007).
The ability of VPA to facilitate the demethylation of reelin and GAD67 promoters was not
caused by a direct inhibitory action of this drug on DNMT1 or DNMT3a expression (Table
3) or DNMT activity (DNMT activity in nuclear extract of NT2 cells is 5.0 ± 0.1 × 103
cpm/µg protein in control and 5.5 ±0.6 × 103 cpm/µg protein in cells treated with 1 mM
VPA for 12 hrs n=3) or on an inhibitory action of VPA on SAM biosynthesis (Dong et al.,
2008). Moreover, these data are in line with a previous report by Detich et al. (2003)
demonstrating that in human embryonic kidney cells (HEK-293), VPA triggers a
replication-independent DNA demethylation that may be associated with an increase of
histone acetylation. Since the biochemical identity of the catalytic process mediating DNA
demethylation in mammalian cells remains unclear (Ma et al., 2009, Zhu, 2009), one cannot
conclude that the accelerated reelin and GAD67 promoter demethylation elicited by HDAC
inhibitors in the mouse FC (Fig. 1) is 1) the result of a direct induction of a DNA
demethylase activity, or 2) the result of an indirect recruitment or activation of a preexisting
demethylation mechanism related to “histone code” remodeling (Jenuwein and Allis, 2001).
Evidence has been obtained in rodents that methionine-induced reelin, GAD67, and exon17
glucocorticoid receptor promoter hypermethylation can be prevented or effectively reversed
by VPA and other HDAC inhibitors (Dong et al., 2007, Weaver et al., 2006) in the absence
of an action on DNMT. This supports the concept that a putative DNA-demethylase activity
may also play a pivotal role in regulating the appropriate dynamic balance of DNA
cytosine-5 methylation patterns in the mammalian brain.
Recently, cortical DNA demethylation induced by chromatin modifications, especially
histone tail acetylation, has been implicated in memory formation (Miller and Sweatt, 2007;
Miller et al. 2010b). Increased histone tail acetylation induced by repeated administration of
histone deacetylase inhibitors facilitates cognitive function in normal (Levenson et al., 2004)
and aging mice (Peleg et al., 2010) and in a mouse model of neurodegeneration (Alarcon et
al., 2004, Chuang et al., 2009). Taken together, these data suggest that pan-HDAC inhibitors
such as VPA and other more selective chromatin remodeling agents may provide a potential
adjuvant treatment for the cognitive deficits present in SZ and BP disorder patients or other
neuropsychiatric disorders.NIH-PA Author ManuscriptNIH-PA Author ManuscriptNIH-PA Author Manuscript
Epigenetic processes can be a target of antipsychotic drug action
Recent work has demonstrated that methylation of a promoter CpG island located ~30kb
upstream of the gene encoding mitogen-activated protein kinase I (MEK1) is significantly
correlated with lifetime antipsychotic use in postmortem PFC samples, with greater lifetime
antipsychotic use associated with lower levels of DNA methylation (Mill et al., 2008). This
DNA methylation and demethylation神经疾病靶点_生物学_自然科学_专业资料。Pharmacological...Epigenetic GABAergic targets in schizophrenia and bipolar disorder. Neuroph...
et al.Disease-associated epigenetic changes in monozygotic twins discordant for schizophrenia and bipolar disorder. Hum Mol Genet. 2011; 20: 4786-4796. Rogd...
et al.Disease-associated epigenetic changes in monozygotic twins discordant for schizophrenia and bipolar disorder. Hum Mol Genet. 2011; 20: 4786-4796. Rogd...
热门文档